Compare Moderna, Inc. (MRNA) vs Workday Inc (WDAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Workday Inc — how do they compare? Moderna, Inc. trades at $135.95 (market cap $56.02B), while Workday Inc trades at $186.07 (market cap $44.89B). The key difference: Moderna, Inc. is the larger of the two by market cap, and Moderna, Inc. is trading nearer its 52-week high, Workday Inc nearer its low. Which is the better fit depends on your goals.
| MRNA | WDAY | |
|---|---|---|
Market Cap | $56.02B | $44.89B |
Sector | Health | Technology |
52-Week High | $174.38 | $247.69 |
52-Week Low | $22.36 | $112.55 |
Enterprise Value | $52.17B | $45.26B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, but maintains a bullish technical signal with support at $138 and resistance at $145. Recent positive phase 3 cancer vaccine trial results have driven significant stock appreciation, though financials show declining revenue and negative net income margins. The company has beaten EPS estimates for the last three quarters, with Q3 2026 results pending.
The outlook is mixed; promising clinical developments in oncology offer long-term growth potential, but high valuation multiples and persistent losses pose risks. Analyst consensus is cautious with a $90.08 price target below the current price, reflecting concerns over profitability and competitive pressures in the mRNA therapeutics space.
Workday (WDAY) trades at $186.28, down 4.86% on the day, but maintains a bullish technical signal with strong moving average support. The company reported Q2 2026 EPS of $2.75, beating estimates of $2.61, marking the third consecutive quarterly beat. Revenue growth remains robust, projected to reach $10.2B in 2026, while net income margin improved to 12.32%. Recent news highlights AI adoption gains and a leadership position in cloud HCM suites.
The outlook is positive with analyst consensus favoring a Buy rating and a $204.52 price target, implying potential upside. Key opportunities include AI-driven subscription growth and expanding margins, but risks involve high valuation multiples and competitive pressures in the enterprise software space. Execution on AI initiatives and sustained profitability are critical for continued stock appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Workday Inc
Workday is a software company that offers human capital management, or HCM, financial management, and business planning solutions. Known for being a cloud-only software provider, Workday is headquartered in Pleasanton, California. Founded in 2005, Workday now employs over 12,000 employees.
Read more on WDAY →
